What is Prime Medicine's G&A?

Prime Medicine (PRME) reported G&A of $17.41M in Q1 2026.

How has Prime Medicine's G&A changed year-over-year?

Prime Medicine's G&A increased by 31.0% year-over-year, from $13.28M to $17.41M.

What is the long-term trend for Prime Medicine's G&A?

Over 3 years (2022 to 2025), Prime Medicine's G&A has grown at a 20.6% compound annual growth rate (CAGR), from $29.82M to $52.35M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Prime Medicine PRME G&A

G&A at other companies

Intellia TherapeuticsNTLA

$34.84M+20.1%

CRISPR TherapeuticsCRSP

$17.18M-11.0%

Beam TherapeuticsBEAM

$34.43M+23.2%

RegenxbioRGNX

$21.31M+4.7%

Sana BiotechnologySANA

$11.46M-0.2%

PVL

Palvella TherapeuticsPVLA

$5.52M+45.4%

Other financials

Income statement

See full

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

See full

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

See full

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

See full

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

See full

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

See full

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Prime Medicine's G&A?: Prime Medicine (PRME) reported G&A of $17.41M in Q1 2026.
How has Prime Medicine's G&A changed year-over-year?: Prime Medicine's G&A increased by 31.0% year-over-year, from $13.28M to $17.41M.
What is the long-term trend for Prime Medicine's G&A?: Over 3 years (2022 to 2025), Prime Medicine's G&A has grown at a 20.6% compound annual growth rate (CAGR), from $29.82M to $52.35M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.